{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.1",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies",
      "version": "1.0.0",
      "authors": "Kristian Kolpeja",
      "description": ""
    },
    "namespace_url": {
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mesh-names.belns",
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "GFAM": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/cf4d8bb88754f036b943b4d94ad96e103dcb7149/export/hbp-names.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "MGI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170725.belns",
      "RGD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170725.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns",
      "INTERPRO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "CL": "^\\d{7}$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "\\d+"
    },
    "annotation_list": {
      "Tau_Antibody": [
        "9G3",
        "Anti-pS422",
        "TN1",
        "TOC1",
        "Tau-12",
        "Tau-13",
        "Tau-5",
        "TauC3",
        "pY18"
      ],
      "Braak_Stage": [
        "Stage I",
        "Stage II",
        "Stage III",
        "Stage IV",
        "Stage V",
        "Stage VI"
      ]
    },
    "path": "/Users/cthoyt/dev/hbp-knowledge/hbp_knowledge/simic2016.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "methylene blue",
      "id": "bc17e9a0bb9e81081bd8fd81201449228e606bb9013e59ebf8a144c733531a8fbfe4e53776b79be7832ae7ea593e80a36ccc93367f04919f6241c7f32ab8e9f7"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "phosphatidylinositol bisphosphate",
      "id": "d5400e29322881f575d13276331d398ade30955cda6d9a86b4b2a4b57f6032acc3ba2ffa71e1d55ba0ad553cb0acab7ad39698652a13e553794e2de00d5b2ab4"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "trans-5-O-caffeoyl-D-quinic acid",
      "id": "568939acd9986319ba3871a2c946739371ec258d660e4763ac34ea534eb03d274784aa85d3c4f6aba89065ba31dc984650779dc6058bed8c72e00e994e7e9a75"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Iproniazid",
      "id": "3fd77d84bf68eea6c65ba82bd82808f776779eb09a888691de6175aac3f47dc3c13df504f153047ef506ac216a664bf2387d32f5e0c3754324610aba7d1cddb0"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "daunorubicin",
      "id": "c8f7750cc3e70c4d6a0a4d895c9344a02d6e3fbea8c87906218f4a04b46e0f1378094f4a5d31773641c8d97cb4a5d7242e4c8b75dce5bf22b206bb922cc57608"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "doxorubicin",
      "id": "9cc469dc0558ad5b1b342f8b0ae928f8ab1108da1d461376ef348e656969424e37665add936dc97e7056567659bc64b3a4232800424341c021db65415fae1e90"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "emodin",
      "id": "ef6a1145e4469eabd2ff780f5d341115c6cc84b06208af19d103f4ed533cf808700813a3ce5970a3baffc946d2e61eed2478d9627ba3416bbef8eea03558f404"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "heparin",
      "id": "4374b8548ac69557a1b3cea92dd62e05515db3c3e3d7fd5ccab0175e73fe27191d80062cb46672a453ad02f3598f015b641d367cbb9e3e042312dbcab159a33d"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "iproclozide",
      "id": "6356b07e4936f2bb1b1f6b96628e2df795ee5d536b4a3f293d3807c789cf6993803f482d2cfade44a28efd1f0218c2560fc315eb304c1dcd5176b802d2e75413"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "isoniazide",
      "id": "6a76b0fed2b8a70b5d38a184101e486f6a8acf4a7eefe69774a5502d4c71589e4d24e2b30357c95afbac79b15b3074f9bd79e8699d742f5ea829053c5f04746a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "myricetin",
      "id": "f0379aa465e94d18826e7d35b8f84a97b2e0281a59e71c8f2898fd6f0e20985a2f034f250e8f7f8ae060e6aca4707ac02fa8610931855136e370cab79bb37f93"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "phosphatidylinositol",
      "id": "37ffb4eeab6a8cf2a8277428473def12f02b3de90c0071536e31d35a6e875191b5943b4d220c3537386c70031cd06ac2a65d1e0ac60bc89eac00bd615e330646"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "quinalizarin",
      "id": "7ac384797eac60fb62593ee04f3e24963dea79a5d82d9fea63e4a1fd9b79030b7c836c73bf2fa4743615f7296e3b8d5b72a239da560aa4e89c9c103851f5c495"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "rhodanine",
      "id": "fd4b23aaf35999289341c8dd0b34554cd9e86209692a9cd3327687e49fbe4e69be821e0daefd4b08512f45ad133206b8671f51459b01678f4073c2782c5a472c"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "sirolimus",
      "id": "102b031a00eed78fd9e5c4236defb90a8995463980f9060493bb5fd3159a3eb666cbb2b6a33a213c749a2b279ef6d149796b4f0b568e03b82eb5c89b0da77426"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "thiostrepton",
      "id": "df8ed0c59b300ac3e896047384eda80a5143a5ebb9625a60d2bdffc20d0c1d3a2ba269bbe878935c11cce604d2b574c410b9780c02441bd7ae97caa1255c2043"
    },
    {
      "function": "Abundance",
      "namespace": "CL",
      "name": "0000127",
      "id": "e0e869618672ee859ce3428fd4ee767073424ef86e33d78abaa2fb49c1e94686395d1a1a79d55b33286bf9a5f17fe458f05fb66dd94b035f9310544ba2c87d39"
    },
    {
      "function": "Abundance",
      "namespace": "CL",
      "name": "0000128",
      "id": "1abf305df774bd0514608141880e4ab728e3809e6203f1c97db883b0c361194dc1464c40febb5e81bb79a29d1e0c2b84a087b55368f3dc7b80364451b84af92a"
    },
    {
      "function": "Abundance",
      "namespace": "CL",
      "name": "0000129",
      "id": "d4ab3b81fe959e03ec3b0777f910aeecbd00ccf49d06cf4fcbed1a75f982af319fd0ee307adbb0a8352188c3c24bc8c9050d475d5ebf1f9e062e3ab3d655b703"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "neurofibrillary tangle",
      "id": "3b50c674ff9633f408e5173562a06cf3a856abc95a8b034db8e940b464f1cea72df6f9fa9b7b02b5daf4eb86a37a155f203289451f7203a7b9c9e6c65313eadf"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau aggregates",
      "id": "2f93b798e33773ea9681389870bbee41f6fa7ee04c087bda4bd1492520385f58d089a7261b1353e15c31d3e29a96ff31884886e6ab9fa477ef8f63f19cf154f7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "isocarboxazide",
      "id": "4cf3738d716a02eb6457ef8eb745a237bb61dab570d9ed3b18eb408f3ff67a3ace9af1bdace1d0c895c634af8cc21a24d783492bb55acec6567f4d1a57ab48bf"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "oxazolidinedione",
      "id": "8094c43f34e1e5553625c8e50233053920acded7cefe617f5ea15a85ebaedbce9749ac1907d5590d4dfde2b0aa00236e4bdae4fa45b1646538b4b8ffb4f275a5"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "sudoxicam",
      "id": "dcf26437423cbcd0fe7354fc4c7b128e2ca84fdfd577cb7d9ad31112fc42890fefd40bc974f5c3cdf4291fa155f9184a9905acc27d818b16d3e3a2839ccaf76d"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "thiohydantoin",
      "id": "f535947e9cc27fd4ae63b9623f773a97dddc9396d3b802b996226bdb85157e3d47dcb97b41be16bc82ff3565e4637d6efa459f8c4f4123ef6829407f598e879a"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "thioxooxazolidine",
      "id": "72c6ecfe87525eed5c6b7e73478b37d037c727c7f8d1e10047b703f6e9f76b6608ed13bc973e715de0ca400f7cfb83839984b142dd97c189a33546b11b0806d8"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, N-Methyl-D-Aspartate",
      "id": "bc0c849274509856f0839b39c84ee4c4d06be886e9c4a160c019e566da4f7b7da0f773b5326d9d72ab53f350fa5ff3371b3cf66ae89e844579e4eb6102565963"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cell-cell signaling via exosome",
      "id": "2e5b65d487c87133cf0698fb05bb2be68ff730599364f9b42166dc21d8c9224cbe00b630b63a61114fba05a676b3cf9780009f2de2dfe9f67be19c0a2248876b"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "clathrin-dependent endocytosis",
      "id": "7639b43ef23b19d79d11020dab549264613ef3e5db7a2daf76d40b01e5234260732f8668affc59b84fc039419743e8e7ae81d1d7b66f55b4c1f43c261aae425e"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "autophagy",
      "id": "f1a3202be460e565f65c1445ee061e99f63cc05f9ab70c5d4d8d93ba180d6a94f65cb8d1ac6c5ba53c0a4d2e153db32135e6a0bffcfdfd4d84e6727594a70b0a"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "macroautophagy",
      "id": "568e5f70e05a1543c9a1d54019c461ab0802ff3556801ad06f2231e0687a80f2cbd21d12f808f5d72752f7cc8c484e0b32d830256321af323cfd08b1b63cc765"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "macropinocytosis",
      "id": "330dd34dae8d3c8832449c4d8b2519f2616096444061fc6d817cf07335c17f0de0c90747636816c810cbed08e2173d202e7b1c511832695ed5589181c0e9fd68"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "proteasome complex",
      "id": "5deb6bcfdcfa66f95c4979205b8144cf23a26c8da492c2d4b71750a7f8e440a3d40a37452d67ccbdccfba2bd5cea7bf1bbba3d66e18875bae3fd8abd8d3d68f4"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "respiratory chain complex I",
      "id": "e9472ae2cab1efe98e798c350785a71a5def60f4b5286f065d4775e017cfe95073ebf67eab42960b24991d6717178d6b0c1f9c6edb1e873f8f01cbeb042b2515"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "heparin",
          "id": "4374b8548ac69557a1b3cea92dd62e05515db3c3e3d7fd5ccab0175e73fe27191d80062cb46672a453ad02f3598f015b641d367cbb9e3e042312dbcab159a33d"
        },
        {
          "function": "Protein",
          "namespace": "HBP",
          "name": "Tau aggregates",
          "id": "1c9d48fe854c1832b8539731374dc5bf3dc2079c9e5fb4e074524c6557c9d37042d9cd5ea71ca88458e22e15fd3f713284ef876909910dc47484812b0a150983"
        }
      ],
      "id": "bcc057cd95fd2d73728653050655a8f7ffddffe23edd39441f4a6e392227e138f36981edce4ad502211bbc570091953ad0a2d7c260971511909f2781019ee3d1"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs242557",
      "id": "955bf122a8496d813d5024d8714356b1ffeba74d753a332f0dc9a5498c7559b4c02f71d4370c68c837d38de0ff42a8194f3eb693188ce2455cf9fe2c6fc77f9f"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs2471738",
      "id": "815c406b9ec0a5defb0eedfa3a73b449a40bd714b4be0497fc08d844d4894d187a7828ec7f6341369c5e067fc0fd336695041e9f5040a86d6f10b60e35fa155b"
    },
    {
      "function": "Gene",
      "namespace": "HBP",
      "name": "APOE e3",
      "id": "1f7180ecd91e4bdae4d29d7baf2aa2206dc0d7d64f9ead8d736e39a21926e0b50e88dcab7219d6e5066035e360696d84f78b29e1ca3c931259295038820e3734"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "3.1.1.89",
      "id": "6ff1992a7139e55636eec801763d708b119fa7a2585084457cac01e1d70def68eb9e70b5b3564df43176b4bc5e95885d92269aea67bd7a74784cce614a2aecbe"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PLC",
      "id": "a954cf31d48b6ddffaacdf9ac551464d6edda5fead07120c8d6453a89aab5a325ac1795b97e6993441005e73dd31fed063aa1c7c5b0b2ac77d1783fc8006e68c"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "3R tau",
      "id": "69e10fce57b3686846f5b3dfc26c631268b84a8a38eb814c13670588e4a660bca26f90187cc38c09c2891f39b1e5b3658911e774ced090fb08173eb8866545dd"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "4R tau",
      "id": "fed662167fa10f270ea26bf05155229f1c1fa7c54b4a2c13d46424e97c1c0be3dd98a23ccf6ebd1605ef472e4f2a923463d37869dcbc28a4bc3c3bf2bf19e239"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau aggregates",
      "id": "1c9d48fe854c1832b8539731374dc5bf3dc2079c9e5fb4e074524c6557c9d37042d9cd5ea71ca88458e22e15fd3f713284ef876909910dc47484812b0a150983"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau antibody, RG7345",
      "id": "7dc822dfb4d3e3d8eac9d658cf5c76ff9408fdf426c71326429ed2bd183212f0b504ec71f5d687c5891276c988d983bc1fe69de64b0b6a541aac80e151598916"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "microtubule-binding region",
      "id": "99043577ba012bab6beaa261af4af0794f0bbf7ec841805dcdc7c837d54ed8ba6ee159ed8f3749148f589a7f75faa8a15068d82c4ead932464ee78fd704732b9"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "paired helical filaments",
      "id": "50de5721e1b866223703ef49fcf748522e974031731e9b7d792667545b73367e544d983be25c15c16bae0e0560e70f9b7a1bad23eb47f7e208234909137c95ba"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "projection domain",
      "id": "385650dd621a10fc5da2ecfb6697742fb09c8f30832981ba0b7dc317aeb874754f17c5198f2bd0727f9c0b294e47dfe46bd0191d6432010ef40db087b3d9f253"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "tubulin-binding repeat 1",
      "id": "f845a2b9ab9383332280869589a5d60e34c53afb41fce96f31da209e73e76633686741f634c3e8c4c6cdb6bd18224da44a7c116862764e777a42e2abe84019a9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CASP1",
      "id": "573c1f59f79260b0e8231f27d98abeece26f3766396d321ebfa7b7b383c97b58b352e2a1d09292a03153a23832e0349cde21b58fd43b5609c74bbfdabf271d9c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CASP3",
      "id": "3fc355e7c574083fad31aa9edc5d5685615c49fd58885c2fbd439371619da84fbe274bd3325695ab21c912b5ea592d8031ffa114a9147908170dc187400ba74c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DLG4",
      "id": "10e57c70ebcfa151dd8a44247ad31919f3578576f99380aa5e432d32d62e5473023f4cf88095ab72f3b5a4542b0cdd9fc471bf965bb6ded586746a4952e65b78"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "FGR",
      "id": "71775e56dd5189dbfd26dcb11f92c57db62ae99d934c890bfa9526f979706d77775a0bc297205fbef478b7824f3b5b27bf4974390f099ef52fd0a48949cb06fd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "FYN",
      "id": "ecffd0427f2e321c9ed5143ca2510464c2fef5432457c332ee991bda79dbdd12ace6375208ee66760cc5b9b7990248651b41a370f16eb9459d2b8682cb0da86b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GRB2",
      "id": "f94af8faaaccda960957759a32709642d7b4d818e8c8ba3ed97d7ba05833b4af9c016e3eb270995a8fbcd1fa75f839418fc6a71673178efd3786e4f881a3df32"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "HDAC6",
      "id": "c6e2cb3c91ba614ec9e19574656eba9d234344b755f57479d99a4d4ff77acc4917594446b9b19f9823e8a8a0d2d457d74b6f6a582d9f360f13df4136d902c7c3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "LCK",
      "id": "e01a7494db504930dec972b29f8a1db10e5b225cb2e9bdefb8a546f8604798b462417e23959e15a82df474279bb080449967ba87d4fa84bac141b8446b229ccf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 274
        }
      ],
      "id": "dd0a384100817ccce038c3f0cdfd6bee24a44f94b8aeed981415420aa3e3f5146bc84c6f4c98a2aac50be1fe68787ef056d2ad5727b5bfdc8b4dffbee6ceaba1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 113
        }
      ],
      "id": "2d45567b15e65630ed1b93e762bc448d9a12567416bcdf836d5398ad517bbf1c094d567f995a02e816233dd20220bafd7e38f7cd7dd41c89a166ccc6743d537b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 185
        }
      ],
      "id": "75b42fa1c0aa953df52cb08d23e7dc966df5307e29a3ae1d0f7818df66e0101f640f6c7c22f0c634966b3f9c474d2f7ba524999afa0d4727ecc25339309e6fcc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 191
        }
      ],
      "id": "91567106b0cc6e1d58876b25321df3319882fa1999664f9826f66c0cbb59c735fd536b429fd9e6aea9f27f2f5a326fb2bd79877052dc613fae468bec7003901c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 208
        }
      ],
      "id": "6d66f6a10862943ed63cfc384e3757160679622da832f5cbd75f0a1b1187e97c3acb12e5afc064f1b83b7b83aab93b9b3e93b507797f2b575759ba7c8ae185d5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 210
        }
      ],
      "id": "fe30f3537e882c5dd3f43b2870048ef2032951e2c9f102125143f32514cf5dee3c2e2c3d8ea179a6263de877dded5c9ba6a0a9e5dff515310fd98650b4eca96a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 214
        }
      ],
      "id": "46b14deb2ecfa74d6446d3e6b46a5346cb195bfb1f14bf84cda1781071705183d0e3122edc843b7716047c6050b9fa1b4c05319f6cdd0e15964d1e33098ed086"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 237
        }
      ],
      "id": "1253693d98b286775fbc4f4d2da854a7387d16ee36b86e5148450178dbd67e1b83bce11e5d0332259b18df0d5f95261fb8da5b78c69e1c3566ffdbda36949f06"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 238
        }
      ],
      "id": "3f98afe734b0571a74435d1eb675eb8f6bcd8f59201d3b4f94f0cf76ff1b512db61971832fc2a235d150fd7d904248b5a344841e460ce0c3cd941f12c20ab7dc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 258
        }
      ],
      "id": "813b2c9e98c372302231ab0cee4d998447b97427cc013bb818555b065f5942ee22e7986edadaea26a29637d0901e8ef0711cbc88c9138ea269e82576f0ebbd1a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 262
        }
      ],
      "id": "c20d653a77090fa48337a73d9915475bcb411eb52f7e239d287da66a8d92ac32ac84146976f90af86f112ccd6fb631b1dea88f465bf333cf545de4f9a44d07ef"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 289
        }
      ],
      "id": "f8a8662750833c70fb5890a753ed342acd2a7565ac70de5bdce6bfea5e2cb6d7822207e4db6435b434325ff01c298b7de12a7374dde2d2dbc0bc0daef4d60fdd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 356
        }
      ],
      "id": "48317023adebba2bdbc3547d0f7ee43578ecb436211b91ef867ec4d820c385520ab83ed151305262f74205eb47f03ee242509a03e3210e94a0ea5a87589d4241"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 409
        }
      ],
      "id": "539ee3c1726a2627e811c0752ecca01c4b4e6805a0d33e648ea000a6c5e846850ac3bce1d7826ac13cf8f9b5a18fc2f59536e12cb0caa084c249ca493ca6f504"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 422
        }
      ],
      "id": "8e1f07e8873c9ebee75ec9b0a1a7ffb03dab9ea5b9c9044f19ab09dbbe2146bc4635b3ab6376ff363fa6042212c12f578c8377abfcf27f1505f826dc990acbaf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 433
        }
      ],
      "id": "169d89993be9696690861c61b095f83b93ca65b5257571545a91c141bf1898e7b442f6a70abe85cd912c2bf663c304ba26bbb5ac17f840034b7e730f1aa5a3ce"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 435
        }
      ],
      "id": "9e30c0b2a4cf908b2be54d9b2a31288e2dbb5fcd3041c7e4c4f6a2ae5fd2339d1d97d969179be59aedb2e6871d860631699db76cbdbd6edbfd7ddbb43e9c88c7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 68
        }
      ],
      "id": "fd1a762ed713b561a5aa9a6e1c75209ca25c87df139632fa91095d155d133427de2ef812a6ec21262925d291415b67511edcba3a99b4facfd6ec098bda50e97a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 123
        }
      ],
      "id": "6aa23f25cd1a330a5a42bceeae02cc5d855176226764066df5234e3d40f52fcb4dcc7daad9b6081578e43e955aeb7cab665ce4a9f688b3e82fb7947d71e42384"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 153
        }
      ],
      "id": "0b51808a15a059752bf6bbcf73ebe2cf1676847795a5970219cb4f39e01e68ec49c291a3702ad661475394e336df429656a4dfeb384076e337993ec86a5f390f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 175
        }
      ],
      "id": "26f7fd6bd59cbf0fa5bc4f3d25bdf460fcd70316cba794b78ab64db9d3d1c7722f124f119503125597b407b479475892579bbb6e4cf37b39c97b19ab3f1eaca2"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 184
        }
      ],
      "id": "5e6936ede9465c5be198ae25c524751d6fe35c809b8412e2c1799577fa25a5d52080dc5663bd2b69e3ee02436d04a507f344c23ef5c3e4602593727c37e98667"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 403
        }
      ],
      "id": "eb95f91ea089241e02cdd2480ae0a84ed872279e3b9ad05d68fc99be26393ad2e54856ce8c59dc98160f11516a0716f7db3560b368fcba813004e1d281cc817f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 427
        }
      ],
      "id": "84a094ed7326471c09539780f71bbebd4af0c38bcb28e4821dde2b6612d2fac6b05bbaf8d849837dd0a613907bc74494ab63e0ee823fa962449190f5a33cd161"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 69
        }
      ],
      "id": "1c3fef289df791ea6eb56503aea0d44632c075f1dc363dd2856b709d7ec9260da9c22df05fbf2c4079a5a446ea6a06994a043102528af9922d18eee2c1f6cd48"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 71
        }
      ],
      "id": "a4623e86c79fcc618b0182637ffaecf134b5e3b9488a3ddea4f1e7ab994969cf699b78bd03a5cd52aba84ce4b6550046c79b1216a5a011c5e011b95e88cc7f76"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 18
        }
      ],
      "id": "5b045c071b780caaf6d0a4441b95389b9857364de91d6676af9d7497e2f4fd2ceda3e2ac4bb7f5e526690284a133fa5fce968527f72d8e1582029f1551a0c7bc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 197
        }
      ],
      "id": "9acb9ed919ba416b38c26f509c6c8861c1bb5c31a1521af3f3219653f2371049ce79f04f51f312bd747ad81ce355ddd88be74d446a2f31110d614e319ce5709b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 394
        }
      ],
      "id": "a6049a3fe7e4c819ff2c683d6a0b4603e380eb1a924cba6add2bf64e44f0d3bdc913d0ba77528062ad380e45e0f41a83069b70e52b528e119678559c79c89b4d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Arg406Trp"
        }
      ],
      "id": "e2c6b44ac23c144aae60bb608102b6b740cfc30e692b52b90aae62eaaf005d3daf38c0847fa5fa3eac5e41cf9ec4172e27a580dadb4f143af0bd607dbfaa1dcc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Glu391*"
        }
      ],
      "id": "80fa0884c528947e40dfa85db933a0b76e64f1e95f3d91e4f733ad5a8461c5d675446b7cb718a1b2ca55c88e0e9d4727cfc86b136efe7b2b83e1d0347dcca6a5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Gly272Val"
        }
      ],
      "id": "02d14869b6daba5cb929814210feeb293db957b1d4509edab9acbb35cacb9d98f8ee4b909d6ea377e35d17b4d69ac60003bc8de4f85b3760be5290b79b34d420"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Pro301Leu"
        }
      ],
      "id": "69abd82dda56f5ab5ce8a6536350e0d44945d6d00ecff099a36fa97c05ac6435b6ddbac8400692d7b1b5c86850a820df0f7558d8fc0ec4d17ac23eae8501f650"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Val337Met"
        }
      ],
      "id": "76963e4bfedc72a5446a25ada3286d4d4b98f67b49cfdae9dad5a1056c7ad560536fb2c094c264540de944e0a8d5ec972cba7a1de6da23e77f511f669b7304e4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PIN1",
      "id": "a4b6cab238e3cf3e494c884c3b540f12c39b1604b07e59f53693996e4bc2658cc64c2c01ccfa634d6236037a0b85aec593bdb9b7667a3f19d8d33e93614f39c8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PSEN1",
      "id": "1bd45a944b5c10f3c058ae82889876ff98fedf45e982a4db6a034e656845574daa76c407b40b21386a2b59045178e42fa90d4c5b8226477d9f5c86c4b4aa727f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PSEN1",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Gly183Val"
        }
      ],
      "id": "ce136c370dd28346d02dbce65147fa5df1f1351938cf0583fafd8ed7d03db33b47dd7f35220be796f0994f1fff5854af67458ddd79fe18176a0c9e69d6f55945"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SNAP25",
      "id": "8354ef5b34ee16cc14e04cab05bf959da036513b1631eb7e2f5fe73aa670ef1f79a5d0eda4064f912ccad361e3b719cde2b37eebec1f91048159ecd91ebc81bb"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SRC",
      "id": "89cf6fe86000d59fa342b801d809a06408db3c65a224250ba500634f4976a061da0e71d6f72c101186d9032a0624af6fc3b50e209815858d6bdb51831883be6a"
    },
    {
      "function": "Protein",
      "namespace": "PFAM",
      "name": "Syntaxin",
      "id": "b924af0695110def671f9142a101763d87ff8f883ceee5376184cc56883c0408b72f33018e6710d2255a53a4e448af29b8f01f1ab925f305e0068e950907958a"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "Argyrophilic Grain Disease",
      "id": "1872c530b2447addf019451510495a69b509757cb3571a6ba9ed745e17fb224f50e5e621592da80ba1650c955a6dbcc1afc771511f316abf9d853f0c9400efcf"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "Corticobasal Degeneration",
      "id": "7656fef05b91a845d805d93948be43a3bc4a961fd572e8ab84ede9dbbc830a8c04ca3da2e7b4e84b25207c032b4b2e5d4e1a6185bc2d5298c222ce9fb8c7d2d8"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Frontotemporal Dementia",
      "id": "65b349369f9bedd1a6220b3923747475397a886cb45f96f65e9aad66d695cfd560911459bd006d087e0ee4cbf06d8829549b3e32854fe68093e2b5834049d726"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Niemann-Pick Diseases",
      "id": "53660bdd3acc18b687e8dfc5c8a0b98d10e8146fab1cdac433e2ac3b3871af2fb192d5a54d29ae5dc2a6711c54655b5d3d33c00be0c4b11a714a63a1eba4e015"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Parkinson Disease",
      "id": "d7f039170f83b3fcc27595412f3b0352cd1fe95f8481a2b1144ce311ac81bb5f0087a0a7e682f498d193e00b8e8fb29908a6e0b8e23da5ef349aeeb4723b9be0"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Supranuclear Palsy, Progressive",
      "id": "06432576e845db5beb8ae7a4c0ae23454b691ca1773f3467bbd58f6ce3d484e768e57b6abbc21258bd43941d8ed10874fa0d45b24d91638ed7e42dcb0e5c7dd1"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "SYP",
      "id": "5564a6ac0af9c7166799d349d201de4bfb9946af2894d60d7ef36ff7bf028fd33182e3be40b0e03456efa1a4975d9682fcc3ff48c3b4da79e2107da3ecc73e43"
    },
    {
      "function": "RNA",
      "namespace": "MGI",
      "name": "Mapt",
      "id": "2b9c14bc5f6a1fc7a618e3033d279c071ef9eb5ee7989e50254f39b8c490642d54b712450230e4f2d6ce7e8e896a75877137a4d4a009b068650366ca083aa81d"
    }
  ],
  "links": [
    {
      "line": 82,
      "relation": "partOf",
      "evidence": "Using the same tau-1 monoclonal antibody and electron microscopy with colloidal gold-labeled secondary antibodies, tau was also found in very low amounts in astrocytes [16] and oligodendrocytes [17], and this was confirmed by tau mRNA expression analysis in the mouse brain [18].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 106,
      "target": 17,
      "key": "3ac68aeb13a26afa2d50705ffd476678f15a925a4873c1cf02e2fb93c4acb1736f175a4f490dc01693bdcb360d981ac797ad1ca5436123f4ff9144ed30eaedfb"
    },
    {
      "line": 83,
      "relation": "partOf",
      "evidence": "Using the same tau-1 monoclonal antibody and electron microscopy with colloidal gold-labeled secondary antibodies, tau was also found in very low amounts in astrocytes [16] and oligodendrocytes [17], and this was confirmed by tau mRNA expression analysis in the mouse brain [18].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 106,
      "target": 18,
      "key": "d3c5ff36cc0ebe28357606e9e92086703988b30bcb25f664577ba515e8a5986a47c1a7232bd2f58020904e4356636460286895392a9a1ae08e5a37f7ef460875"
    },
    {
      "line": 89,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 84,
      "target": 100,
      "key": "fc1e16d3e43c097079610881ff36a7d5c83ef0e92d8140430f84dba31e58bff7cc9e72340c87dde38539b88c385c4b567b22dc4d939e0cbb5ee31839942fd3a7"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 84,
      "key": "9cfb692e3b39903e05776d10e5ec184405b65b7ee2afbee7a958ac60be2e0a8de0d684efe5a7fcc4198d4d76591b906798952e7cda8584eb982d9758803184ed"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 75,
      "key": "58986c791f2e9f99e5f781c0d69ab10d244a9a868bf00afa6fa0816f18a13812a6dccae802411e9fef1b837d251d13ea81f00cc45f6a72a58a7493509453241b"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 82,
      "key": "5397fd32265c905a6792f7c5cb5381db4b46c62fef27f2a5b997d8ba981ca2c9d3b338f432309425570a0ac71b345251b6534744793ee1a57fbc1bb33a734428"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 83,
      "key": "9946aa2b95523f16edeb9d91887cc43c97409fb07f17a38fb069a0ecc2b60eea026aef342cf08dc43f39c16b3ee15063941a692f0b1c061d2232bd01d523679f"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 59,
      "key": "26e2c1f0f2cf7cadbd4e42d4b3b4bd79417c1af3abb72efdc6389347f1c4e78f3817ec8f10203266fa8f1459650cfe3419fb3b6e7a04d170a08162f0b5be6a40"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 76,
      "key": "6af95cd3daa66f301c13a26a4b037321a9fb66a678d9f64f2d19d2bfdbe9ee159c6fd0655a2fff897c669331bfafaee10bd3c7b7f32325d97a1340077935e971"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 77,
      "key": "84e8acc0aa10f59a01f26ce977684a46fa9010b398561e2594a469634430a7cb85e3a15e33ddf4c30372aad96e9eb97b3883943ba6cc0be87b35b5970d1c52b0"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 78,
      "key": "853118bca69b576a2a4a46704657df9405d5104fd01a8f488081a80842b011145bbd3f09d71ccc746bebf4ab5b819a0baa3f0c184568769348885ef61f50904c"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 79,
      "key": "f7392e0b951faef5a91ea100fc0ece624cab52e7e1bbb3146b24727b5b5e8fd242900dd5067925624b40086aa6d29a08e64eb70b9b6ed8482b4eddbcc997dafb"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 60,
      "key": "8d763fb8cc515a10da84e1e985c0044693b017851461c4ce766f78246936a8ed37510f0baa19cecbd401b10898b937c5a1acf0fd9c09f4b1499ad86dba28fa15"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 61,
      "key": "307167a600941985823e285304ad324877a8eafe275c0102fe64aea696a1384d2561f18fabac841712c952a6375ab0fa8fc814c0538d76bbb9f6dcf06c9ccce9"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 85,
      "key": "b5a7580436fab73483c3bf632d8d96c31184a0db526b830295612a8803372d4a10f1dcb86deb274827053122aeb2c70c8301b931ee0b11eabe854e38f9a29917"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 62,
      "key": "3b6ffebeddbebde6c3905b01aaa4be230b94b17322cab62b5d8c64683772441e4eab8a1a3bdc3096a7cace38d5c493f74403405c847500990d0def53c38a78bc"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 63,
      "key": "7391a54abfd55423811d434067fd745d72a2f722a56868eb1338cef88c90901f5a8111168581998fd4707fbea406351a9877b6c8483e9ddd61218759c52b2080"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 64,
      "key": "7e2720882d6fa374e003f55619af6acd72fd0b6b0e056fde3d6279807f12e1a267d65521562730f5dba91f947c117b5e137ea104b51b15316054d30a3af35372"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 65,
      "key": "8f1ab924405f8e4b64387d57b9e93aaf0f64285cc474dca7562ff63298b2c3c37ef2736dd341c057f4fdddc7f47801603db36c08750ce2e1d7455affb1e8affc"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 66,
      "key": "a76c10c9bcf6ebecd615cd5e760cd39399f3b556aebeb8fc76b2405796231be03deeabcce99d551d194342a20e46898528c6f4af2f0c7acfd6a62eebf1f21c5a"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 67,
      "key": "080e052d346c7207b5e8d99ee6253330bf52cebda6a7c9f26bfc6d05416823d810affa9cf5c7e991ed9f64d7d76eaa4f3e71bb9d233f158a8e5dd972ee06f7f8"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 68,
      "key": "7c4dab41f0b789fe1a52f61758835723c3b320276f1f4dd19c15f5910c60497a112c4ec2b291ad3da3ffec9bbc530290dd67b167ac4d3ad55e2338982297e705"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 69,
      "key": "1b09944e54c63ceda69aff0e55d2784333b55f9cc3686da1e19f5c35f602f7e628a32e898ace34bfac83eab37e5796ebc6eb6ab862f754bf46307ce4b9edc150"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 70,
      "key": "1ea70b1fdc71c02106277625f2caa4a966e913c03fe8ad751981023e6b74cc994370be7baa25ecf05138e10d08c4f2af7320c3a733cae82b6b055734105d1821"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 86,
      "key": "f331474061d8420a9d0b22a9a209adeca0b96c80867792cb1c63830cc912c379a03f93fa521f0b83be162a4d1dd520b68c8d8819746325caef389ec2dccb2f34"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 80,
      "key": "70bb42654369e9156dad866efda47054af4e2d3a10f1bfc9827c6dfe9f03d13855f63d5260f9ff8d90c3bfba7f38342019a74f0bd32758288754a0cb20a5ce15"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 71,
      "key": "9bae280a28a0f7af1bddc5b7e14dfa5ea0abd59fc8a942651e577f658624e9ffffd8003d3eef27f5898ca65e3a0e76b6bd0a6c97aa75f3f8761023e6ea27020b"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 74,
      "key": "ea9c4ec49db06f14df2fa2c8ea89f71ed0de857005fc7644e5b763133bdbd5ba7d77397fb959c529b4ab78a5dba94abe1acdc7b06c3c7957767e7a938c293ebc"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 81,
      "key": "b6d004a88e78d2a2755017f41e258be1af3b715fca02d7e5135708759f2bc1d2d854175cf09021c4d9e4c0c2339207d2cad881d8e1da04a31b1e6f5970a2b0b1"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 73,
      "key": "668ccdb77eecd40539c9e953f53c103cc890ea75980fea28d46ce7e3b401c3a815c17f2391ce50f9736112b8ae0c8794537904be0d2270a702ffaac245bec798"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 72,
      "key": "758dd3f9f47d2ab5dd8538f81b0176cdeebcd1457b9595df319a2eae964617033716ca7e93bd32bda8d8f5ede1e80bd525915e1fff2980ba8d6b0a7ab6e7dfb4"
    },
    {
      "line": 153,
      "relation": "decreases",
      "evidence": "An additional “knot” of tau being entangled in epigenetic landscape of neurodegeneration comes from the finding that by acting as a HDAC6 inhibitor, tau is being indirectly involved in both (dys)regulation of transcriptional activity and impairment of autophagic clearance by the ubiquitin proteasome system [81,82].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 57,
      "target": 55,
      "key": "f4fbd21c80321656d876bbc30fe9945997c452a41335e60f08dd30c4837247ae0773920bb80405cb1162ccc434d71e8502135109b4fae3dafc67f5ab8dd9aa06"
    },
    {
      "line": 154,
      "relation": "decreases",
      "evidence": "An additional “knot” of tau being entangled in epigenetic landscape of neurodegeneration comes from the finding that by acting as a HDAC6 inhibitor, tau is being indirectly involved in both (dys)regulation of transcriptional activity and impairment of autophagic clearance by the ubiquitin proteasome system [81,82].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 57,
      "target": 30,
      "key": "490f65ba4949ac43669ba9763e4bf075187907c4db08e7aafd0de11661de8d96e854cba00ecb50b7b2d826c336f65c34ded616554c234d56e9a72d530fa7de5d"
    },
    {
      "line": 155,
      "relation": "negativeCorrelation",
      "evidence": "An additional “knot” of tau being entangled in epigenetic landscape of neurodegeneration comes from the finding that by acting as a HDAC6 inhibitor, tau is being indirectly involved in both (dys)regulation of transcriptional activity and impairment of autophagic clearance by the ubiquitin proteasome system [81,82].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 57,
      "target": 33,
      "key": "faacbdd86a5739c56797bac42d4605f100b74d7f4fc48487f067bd10665f53c8788139df455c38c20620c2b2721ae582837e05643d734616dd76d007f5b6fd8e"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 90,
      "key": "22a66102eb7ed43a8161d57177ac2432b8efbfabab3d503feffcd533074b10723c8f4779d1742d699a20b9f2075e0382190e440d27216df7140376a51c33ac0c"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 91,
      "key": "80f6dbd9d5f4cd94a43ed5e9fa36c0d95ff399a19f3590e5214f0a39fc4b6694b922fd86728f068084f4cf3f66026c36c236e69ea343f97b99cc7ebe9454d7d3"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 89,
      "key": "62a45f17b83cfb6b20d936779cf9f0724799d42a7844ea847ef7324bfac1f6cf0fb496948b3340de9aabecc2753ce39e56abe9a1af41d9e125d9e184cfca3bf2"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 87,
      "key": "e2e938bb0b35b668961b012e725e5e18c71d04f56eba0c156c98b789b5069843a1fe599925caf5303c5e6cce444e0f7a91d6e50f01d331f35fa1a403f784f313"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 88,
      "key": "325654f53207600694e1af67b57104ea5f0fbd54b1533d1283d04052ec4dccbee920bdf7b851e3adfe341008e072feda17fa783ddd19844a0bb4f1924a24431e"
    },
    {
      "line": 217,
      "relation": "positiveCorrelation",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 57,
      "target": 29,
      "key": "27e0a436c6bb56bf628e030e45ad825d06601cfe2fa2b044bbe7b2aaa99a7cbdc9ddf9844138e6cb6834d8cc37cf45e9066632782b1694709004ece076421478"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 58,
      "key": "69c01b0d6c247180799c5c9e06f248562b622a3bfef9d7718216b5084448efcdd928b55e823d5a1d86350962633367c3818de3ca83844d5a405a6e9e9c165590"
    },
    {
      "line": 89,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 84,
      "key": "a50404f6c10945c684ad89246bbd23f7c908d89a8dacfdbcd9d39e92c2454d3aef457e47a7b242d805b08773d6c3245f1e1925f7a04fd01b3094372409d927cd"
    },
    {
      "line": 90,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 75,
      "key": "25f03ad4df3d5df40140d373364e7628e1deebbfefce587cccae93135c7cd958349db00434cf27d4a3963c182eaade504873eec8264f3d4efe4f9927f363ae76"
    },
    {
      "line": 91,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 82,
      "key": "d2ef1876b8ec60271d50d4095e96518746e1773b151d73d48d327fec3821068d951336afb57dcae79b3c9b60ffce58525ffef8cbb0169733da9d5f4c97381bb6"
    },
    {
      "line": 92,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 83,
      "key": "12e852e38c75c088ce764c8d0c1dd0f50f93cb749b474c3387856e0c47e03fa8c161c0532d9a148987874e6647e7cf660ab49e8e3b862e295b8ea344122f2127"
    },
    {
      "line": 93,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 59,
      "key": "8ac17b52da876c8a273b50f5c0e15223e8de450d5578ca94440ca3b1dec7b31bb33c339c14035054750e436c90ba5902e48292936fd11f242df3fb8aa4faed63"
    },
    {
      "line": 94,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 76,
      "key": "323b7e517af09eaaf419c917d0708cf7d02dabb09b5727c435fa0eef385d0c11ba27b9f55f1cf43e5b2e36356903236eafe5a9152195ca035d0418fa521c71a7"
    },
    {
      "line": 95,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 77,
      "key": "aeb13f61f30f2dc6ef8a7f2a282cf99eb1d08d8674ac9536d00f3576ebd3641fbae7e2d2c65a7d8460f8acf19fe2cd875142be49b6f0fb5f92a2c4a2a6185865"
    },
    {
      "line": 96,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 78,
      "key": "53c424e67630e0dd1b9139ccf2cff5e88f914bb399337e27da51e1c7d69b6a6aae38558f4a6d1df1fe77a84be9e0b701089e721d5db74c8434a643da912c7d3b"
    },
    {
      "line": 97,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 79,
      "key": "561eda4a4094398d7c3660f8babad743ffafbfe96bde6befa38455a9d7220cbbcdd55b371490af1da247dbfa5d2bd6be685b3432b995b107ff3736332f4c3c3a"
    },
    {
      "line": 98,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 60,
      "key": "552a8d18dce3b24a0c8d51db2b6e355947bd79ae42ecd12c063a7c47d84b567dda868332358c58a97232be2e22a3081eefd30c98daca221c33a17391b4acf5d7"
    },
    {
      "line": 99,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 61,
      "key": "f2686388401733ab4b1692d0cd50ffe90c9181290c264c1d815c6d4e11d8b865c89b46332e18d3d39213b674074c8eac6d5334a33a7e47cb8428e7f204526a80"
    },
    {
      "line": 100,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 85,
      "key": "cf935a2126a717946e7a17c598c6fc5ec776dd25ff8f672c6efb29cc046ddcfb1f7022b9c7e44459ff149b3d28d60e071926c2c26277267edb3be1d0753083ee"
    },
    {
      "line": 101,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 62,
      "key": "40592d0a51c7bf1474f56d1a95f6bb976320ae1c76b05f6e6323245e05fc9bf6345911661a3f245cad67dba80513060b600b08f515a3d6e88dba77c80ad1bf34"
    },
    {
      "line": 102,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 63,
      "key": "31acfc29a0216786eba05b308489cb34627fb4645c7f0d3df4fec9483791f759eb0ffb6cdcceff69012b069038e9bb46209347bb770f4116b1a75c773c178d92"
    },
    {
      "line": 103,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 64,
      "key": "bdd528b74a6ebb74956992611bff5fe2adc9370ac8f14724b28a3b9e0e1420eb40b5a573bf17521e6dce8c0c3c8b6e3c129c7f4ed7d6c1d0b30678b3e378139d"
    },
    {
      "line": 104,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 65,
      "key": "261645c461f55f282ef2300b8ceae1c8b2e5e5e55bf9dfe82404e550dfe51d7e93d66129dfdb3476a823dcec8c74f94eea66ab0438815f516d6b7235f45f808b"
    },
    {
      "line": 105,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 66,
      "key": "05ff4805647cfa70702de12d0273231fbcf71d2a9af9fae60e37d526d113f63c2d7f5b9b176228539868e9cbff708dc963d1fb63d722dd5a7bc8fcb13f777c48"
    },
    {
      "line": 106,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 67,
      "key": "a2359b2c2a37d75d734be1cc29222e9c5bfd9bcedc9014397c495d1bff428c6d8d292899b1802a770be823e32d34f885cea3c0e46be82ee60dbe78d7b4324cd6"
    },
    {
      "line": 107,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 68,
      "key": "2bc025cd611293f61150b94fbf714e4dad4775f1e79ce20dcf6e207dea1d58c38ffd771a817669f8b8d9caea9bb8b7b0ea359edaa86c0ef622921c18e060fb34"
    },
    {
      "line": 108,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 69,
      "key": "5f00d985c797a3793f168d7883ece7fe8e63a5c90666dfa76eae401bca37f81bfdb5bd4b66196d71eab7cbe5241a98f07bccc1a0731737e649326730ee4a598f"
    },
    {
      "line": 109,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 70,
      "key": "4dd385942760f56086711686a72562a264f427bb36201dc8961a5af008a6f2ca371f6f29a8aa5a4c07298c22ef9623beb2b305bd44db5f2d378c57f0140fdb4c"
    },
    {
      "line": 110,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 86,
      "key": "f6ab58c20358f8f61a306f217b95394d9910ab052e676fc36731e20ed1a8d1f05fcfc2f577614f920a3dc8136af1d559ff1161b4c779bf86adbfe94e90a04da8"
    },
    {
      "line": 111,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 80,
      "key": "203b267b5220475eb68fb2d9c20b7537e07dc7e051ec69d4d2bb2d87846fc0e178102f1e66d53dda1f69f142dad6a37958f3e406e78d0f16ca61e0f5c8d009ee"
    },
    {
      "line": 112,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 71,
      "key": "1600b564192ad8dc18b9208ece455f36bab552f80d95617ae6da6a991f47a8fde7e7ed118df1a8e081a181aea7fbeabfe8f76fd2a7d2278c2ad9e348fedea4c6"
    },
    {
      "line": 113,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 74,
      "key": "0c2ea3824d5f175deacc97652d5be58cd323d6327d15a4bf61c7a12a5c4126cc2ff9279110053a93d23e8904af2b1cf6186c5b7a2a85d29e53f9fd88c7683e61"
    },
    {
      "line": 114,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 81,
      "key": "2f628ea2e48754cd7734ea930d66d98c71909d00adc0f2c433ab7d3402ec483dbee4b263f59ecc38386ce8a049c63ed1f4d9826571a805b871435e580a1336cb"
    },
    {
      "line": 115,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 73,
      "key": "66e8b21d031a65dd9472856a06be818451454502815bb2cedde0d7f32d2af3ab55c00ee3aae33eb001795bc80505331d9ed7414a2ee2a8c8dc8d20d2dc566421"
    },
    {
      "line": 116,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 100,
      "target": 72,
      "key": "9925ef0a7b74f27240339dc89a30fcb37dc698a2a5fdc40b840184e6a77f8c7fe362683ce33cfeb89901ea83a6f5ef0f1d2f91b238a1009eb438e6c117bd5824"
    },
    {
      "line": 90,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 75,
      "target": 100,
      "key": "e8fb2e852d01edea8f6964696cc3ef47fb4eae7338eaefbe25f0ea14335085b3d596b4aef89578f7eda895a35d8b78cf42d413142854e3e0baa9923c8912fa36"
    },
    {
      "line": 91,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 82,
      "target": 100,
      "key": "e0ddd3dc7ad26d80f50c57a146496ec96ea7275550900e90301cd17b7e880e44eef88c8da39c478955f9307dbfd86eae242e2b69e9eecdf40e2d29825cfdd3ec"
    },
    {
      "line": 92,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 83,
      "target": 100,
      "key": "cfcba9f7d43462ce9ac835d6febbb5ab118100512283f634279129329f3f7a67d42e5c32b7477ce8f98c3e1a3bece0dddfa7c5b6ae091fa4d390c9661891e9d3"
    },
    {
      "line": 93,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 59,
      "target": 100,
      "key": "c67fb751dedba8ab132cb9971667154d3355e5289d6dcd136ab559b6fc0634c9d11a6df44c7a84830e87b3449ce74497a57d7dd61c8c51dff410e39181c4c6fe"
    },
    {
      "line": 94,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 76,
      "target": 100,
      "key": "18e9f750e95fb6f123839c0871d7d3f2ec11db2d9dfc7b11c4b918fb306137c9fd31745f52b415beb24dd5a8d5b3edbdf25421c0f7d084d0222c8c6448480f2f"
    },
    {
      "line": 95,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 77,
      "target": 100,
      "key": "6f85e96a3bd2bfc3384794b2d1f2cfc330170f9095cc27ae9ec8f92b97f81729e24cca80a24421f3ca8e6dc4bb17c4ee7b954eed019142fe9257361455b7ae9a"
    },
    {
      "line": 96,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 78,
      "target": 100,
      "key": "5ac79358f2bb6e39592168f92a34b50c278378f23c96266407576e9effb11ac67835ba906271d917fca87796ecc8ce1e4c6062111fbae98de035fbc5b62d9657"
    },
    {
      "line": 97,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 79,
      "target": 100,
      "key": "e4bb6c8bb7a182595a6fab4442b0baa42ec3a1d892690f0722a9505ded1355bee46c08da3f6d191255f2e91649b716e7e93cebcc1ee68b46baeecbdcf2d8c59b"
    },
    {
      "line": 98,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 60,
      "target": 100,
      "key": "458cf9a627e62157c7acdc48912a40540f97478da48f85b05c57bfe89466fac75049fb979445d7368dc4769b57ec8882426115c8d2c21920b2a105cf8e5adfe5"
    },
    {
      "line": 99,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 61,
      "target": 100,
      "key": "983026ec0ad5223593e5a8ee6fcbabefbdb46806b0113340993492464738b09a172237280c0209598920faac92ed06d053000b5122f025e0c35a368e8e6692d6"
    },
    {
      "line": 100,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 85,
      "target": 100,
      "key": "4cf017f9f7181d44b7eb217ad0fa36d664d0bb190a4587fbaffc1cf4ff2a3eff4a327e06ef6a6d49ea9854dcadf639312197d7a36f8f39084bceb9e316043b46"
    },
    {
      "line": 101,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 62,
      "target": 100,
      "key": "f3a350abdfcac8b88b0af1cb06e239c4650191071ec04cec484c6c4b6016e8d6b81a08348f5649d6fd2a39c0bb57e2469d9818265961630ca40625c924174ccb"
    },
    {
      "line": 102,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 63,
      "target": 100,
      "key": "9b172c1240d48ccb72d1c18e945006682f1226d6a7541fb90fded5750ba2ac4c78bf84038b736af8e1d632cc39572b0faa61418d61e14c5475c4447e98950ab2"
    },
    {
      "line": 103,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 64,
      "target": 100,
      "key": "5d3d969990ea39442a29bf242cef5c1e59f44ab51a017312176368abe2123b88796e03a1b25ac89e224fee67c6f63a11d7864dcd06bbf1308e1192d1a6a89dfd"
    },
    {
      "line": 104,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 65,
      "target": 100,
      "key": "e518fe4a49e3f8a640e001e4c60b7cc424187d760a7b5ddd53b02ba66f6c4a24e3bb0e9f1d6bded91ee4ddf2724b097a7e2a576976458c0b2b1f7f9b9a170adf"
    },
    {
      "line": 105,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 66,
      "target": 100,
      "key": "ac27090db1aba6a0df5f1d53b9b908f0c0ebf8c55f836e8f028ecde0c067983606c73b7580a5e00f76e425838549cd0b3c767da12456868967f6fec6f4be0166"
    },
    {
      "line": 106,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 67,
      "target": 100,
      "key": "0744df10a89f1e831d7dcfdb78eaa3ee6ce838843931cc065165f6cddbe024b9675ea71b96c80c9690f8dbf5934cbd48c80d25ddcb958e941bb7dec22a8750cd"
    },
    {
      "line": 107,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 68,
      "target": 100,
      "key": "ffe94231170c9b77a28a345bfd697ccfc9abae84fca5b58938962a3eac8ceda5d09e78be0fc3549ff544f34e28cd9489a8f9117e01e3fc90cfcf0ff9deecbbd5"
    },
    {
      "line": 108,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 69,
      "target": 100,
      "key": "5ba262ecd81609b34de528d8ff5ab8c503e0598ec5893384bcf94eeefe82a93fc77c11ebc1ffa1c49b6399417b2b849866f0dfa6f1b16661f697181b465ff1d3"
    },
    {
      "line": 109,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 70,
      "target": 100,
      "key": "e36b4fa72d09609ecaff933f5a3dae911fec47fe95c23b19f850b94886c8741f96fce7ff6d71008101b298e45557b10a3c3e0f73ac4dfc85dee54868f63398b0"
    },
    {
      "line": 110,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 86,
      "target": 100,
      "key": "b0e2748ab9d57bc250d5d7062271916cb710fe577bc441ddbd74a67c5ecb48aad9b9d58b7c567afcd84e7e3fe88322f6b3d625722093b9bde5e64369a509c537"
    },
    {
      "line": 111,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 80,
      "target": 100,
      "key": "8e5d9d7f608e8219797f3dcb9d7fdf05be13fea764c7d3ce7ce6c7104fdb520ac44baf2a3cc12d02f843842b86889fc41def0c88610ac5b8402756b1263dd681"
    },
    {
      "line": 112,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 71,
      "target": 100,
      "key": "5bf9e384246c7807dd4f3726275e8982a9c0e7746422a05acb95103b3cc1c3bdf8bab185f3eff1564a8aea177058c2568a24a893e98a94ebcdadb27b7cedab4f"
    },
    {
      "line": 113,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 74,
      "target": 100,
      "key": "65c403254636d27e19e7cfdf92aeee359414183d42c81b26bd316086a207881f4f420457769fd5875f2419bc208b3a5f3ecedad7daf033b77cc0b5d22a55fcbd"
    },
    {
      "line": 114,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 81,
      "target": 100,
      "key": "8e74d4e43b7ea16f1e5b8a9fad175ec232634bfb7fae33678bc9a153b9f1b77066106e3ea3c4abc5d9a2673a2d7ffdbfb89cd203cdc4adc65d443128eec0836c"
    },
    {
      "line": 115,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 73,
      "target": 100,
      "key": "3771e9a88a0c0980d7101675294841949b34b5b09cb1ec4456cb35bbf9addc81faeb7b5f37865d56d1edab7c0bf0fa6d300a614ed6d26a26c382171384ec3d97"
    },
    {
      "line": 116,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 72,
      "target": 100,
      "key": "9e038f859f08b66e225fc8f67f3f20182519d38ba090cabad0fd87c5902996aad8e21ad8c176ca448633ff6a46f6d51efe9a8689bc37b4c2d48f72a06a47757e"
    },
    {
      "line": 239,
      "relation": "partOf",
      "evidence": "A quite different strategy is to target tau clearance—e.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 72,
      "target": 43,
      "key": "13a4ee00013a50b8ec6c291ef3fb12911cd74881e19359c16342c18bc9f831ffd5706571cfab135256baffa9729f4f6d69acc3e2ededf06369d45b604f95c99d"
    },
    {
      "line": 122,
      "relation": "association",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 45,
      "target": 55,
      "key": "b4c90541ed0e514837b21ea8b5e5dbcd92ce31cf1c211d43349290db2d8ddfd1c824a791bcd23ec517ccdabd330439baa8c3bbbe48c600b40221fd7d507d077a"
    },
    {
      "line": 126,
      "relation": "partOf",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 45,
      "target": 57,
      "key": "5140a3e0c50b4671af1315fc8b3cb88537c10d8d89890a6d7467b4cbe72ae41b61065a130a51eb783c33540091a3ccdfca66512ab505ca5d7682d1ef231c43fd"
    },
    {
      "line": 122,
      "relation": "association",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 55,
      "target": 45,
      "key": "d2d6e89ef5536df6782bd061b1754e4533f3511a1d127ce199e13fec03ad379fdbb1bdf3c8293226db78ac0dc9d04c97e6ae47c7bedf5d792e96ff544da74542"
    },
    {
      "line": 123,
      "relation": "association",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 48,
      "target": 38,
      "key": "6ed063ab8ed40c4134a294766622e116e622a494c8ea451b3ad9e3c844f4b4f853277fe6035210fb6e8363f5372fed3b6c239a9d1f695fc30b2862a641d8c2d0"
    },
    {
      "line": 125,
      "relation": "partOf",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 48,
      "target": 45,
      "key": "90707e6ac84a8b4f198b000df105d5467af5aeb00e0392b40b2409cf4b84e0885509410db46ccdf3087446b0da24823d5b376c2f21084303bb4a654e16b824f4"
    },
    {
      "line": 123,
      "relation": "association",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 38,
      "target": 48,
      "key": "f24725471b33f6a92a1f7b034d744a72160e34229cf0c00a2d55803085476a8d8e46f466eda7876d54a052fba100ac6db81529196d13fb7d8e391b50e761ec99"
    },
    {
      "line": 132,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 56,
      "key": "825253d34fe4ac8c50c9847811285a91c0ea793ae4afc348ccb063b5d72b556ef82244d0a275d6f07eaaf03c92074c444309149acc69bf23e86dd91813d6f32d"
    },
    {
      "line": 133,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 52,
      "key": "eb8dda0cf7c4ab9b57397ff95f2d2f31665e8215239992077c9879790786ca0d7aeb821585b3d1890b2216bf5e6de9f0f13abb848faa9c46d97fc56794199177"
    },
    {
      "line": 134,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 96,
      "key": "8f213feca3c674f4cb9853921d2f118791f2bfb1e15e5e9b5530e7d2ca0f7dced408afa26ddb658a596339c68e06975601df24ef1eb064a0fd35a98fb1a685c5"
    },
    {
      "line": 135,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 54,
      "key": "bc77fd5666993878345e8a5fbf29ca89723b382414424daaca5acdebe022530f5bd29e7f80284b921cd54fe5a678af1ed28a4dd2ddf6a6df6512377c3b2d7cf1"
    },
    {
      "line": 136,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 40,
      "key": "22df74ceda9ab6f13afe938b92b93cbcc3b60dd63aa26ff0dbebedb9d5f55d9dc23c019ae9f762d8efbcc69561a7d72c109715a52c86726fc3e3e8a3b513c9c2"
    },
    {
      "line": 137,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 12,
      "key": "cdd014acab9438d6c5a89caef0c191ea57c15bb228fb2a2bf30dfbb740e4dd1b7dc5b629ff92613ac4d90fad748d1185897a0e6f7db501bd2d920f36d4e34c45"
    },
    {
      "line": 138,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 2,
      "key": "d98f60d4860b8530243b5956bdf3011e8859e9a84e9f544f65d2232949b0edbde6621327983e634b2c496eeb143fbef9e81b1cd4379e7cd3be906ed48aaf8292"
    },
    {
      "line": 139,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 92,
      "key": "06a816a71ca5541b8e3670a605eaab4b4b03f449e9cf9da232cc0842b8c74ce506423a94402591fc0486a76a64df05224bf5b50cbacbfcb76ccfbc3013e31b3f"
    },
    {
      "line": 141,
      "relation": "partOf",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 57,
      "key": "51f6313d95fe8a386745cfb9f185a31fbea9f5783eace82aa9331146c769b2337cb2cc70533c66f7fcc5b0376055cc79c1c6cd62fc8f76b4eda45987c269568f"
    },
    {
      "line": 145,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 53,
      "key": "43a4424b7d3477007f687dba574b2a30403c8c7c18c194c240f2e9882e6fd88bb942bedc261ee17db096f0f8e1b3be91b024af9defd90d536304413b8bc21bfa"
    },
    {
      "line": 146,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 51,
      "key": "dd5a04650c993452204fcd5ac212f3fb383474415781250f194df72cb3c8f3330c4c6d8d9862e23fa8d7fb4eb05cbb4de23434a4da0333bc0dd762fa2b8d7404"
    },
    {
      "line": 147,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 47,
      "target": 27,
      "key": "ff01ac271f73f8474f2707efe62e3f36d8f4f46e32b44e8f096d840650acf6a8f36517735eb616759925be4f6a7a3d544dfd1e78646839577dddaa4a96c2d70e"
    },
    {
      "line": 132,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 56,
      "target": 47,
      "key": "d28872c35d6cd3e9d8ae3b9a1b50b1dffcc6b60c46c9f2be0ec297986487800ea477a5a8f6eab2c09b3bca8c1ee9a4a028bcd9b1450d2d0880d68ed01d46e646"
    },
    {
      "line": 133,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 52,
      "target": 47,
      "key": "9a37e5b59afa1c101397deb987153170f6ad6951cb6585ec7a1997d21f4e01ae9d4cc7616207e442244a7908f6419658cf166eb8d307036fa9a6b504515cd216"
    },
    {
      "line": 134,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 96,
      "target": 47,
      "key": "82cf19ea820d3ebc4502cfec6571047449282dd0677cf31ae795174205b4711f77162159e80caccbaeff7726677c0d3a6fa08235fc89f48f04282a004286dc92"
    },
    {
      "line": 135,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 54,
      "target": 47,
      "key": "48109c7609711c9c1361061a2d9de940756255f5adc431030b4ed484d4aa6017dec43fbc684d7e8ff764d524b5b69f127072948f53348c544ea131525dbb24e7"
    },
    {
      "line": 136,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 40,
      "target": 47,
      "key": "51a101ef644bd4e3ea50c139c881001a72c0ffc64381d4e97b2da4988b40fa4dc2b758fc14791ef24c565cb31ba0982440bcf094410d65189b3eeb3a67971faa"
    },
    {
      "line": 137,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 12,
      "target": 47,
      "key": "dd919ef885bbe2a101cce1705c2330c1a28d94a6a82663bf6afe86426c1b88eee892f71af9ef5a7326f28eb95587b062c7a631fa11c032a40e782ff1c8e8a8f6"
    },
    {
      "line": 138,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 2,
      "target": 47,
      "key": "38745ab861c70debdb52b8911d9f619a63cececf78b7d87dadff59bd3514042bf0d4f629d47ba119c85d48985a9fa04abf8f37f7651c879428c675bd4ba528c3"
    },
    {
      "line": 139,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 92,
      "target": 47,
      "key": "a2a28d4a71fdabe1e9a275c661b4796cca790e15f3f444a3580ae7751ce6cb7e60bcc2082a7c9a0d58fbf1ad868e7bb5aaf5a9415badf91c50ee492728f13cce"
    },
    {
      "line": 145,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 53,
      "target": 47,
      "key": "22037065c5d3f67850a89f229c23ca25bafa1cd328fa0ce31c1fef39fe7542b2764f637a1c461df1f503b9afaf14f9fabeae473a559dd6b7e7bc2c6826ce5f8d"
    },
    {
      "line": 146,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 51,
      "target": 47,
      "key": "cb7d9b5c6ef6421a26ea5751258cf948aefd1f5f62b2cccbe8aaff2825dd46bc3736e2ce6a6c5ea22b3a8c61a568f9be0425a85f418c68df0c775a84e9ee65b7"
    },
    {
      "line": 147,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 27,
      "target": 47,
      "key": "eadbab1dd0725eb23897182bfcff21ef26c70525bb3590330603074261e4cf306c3c50fc2ccf6e2ba9c413d5a1bb05e3c799c6ba27291c743ad516fefb13089a"
    },
    {
      "line": 155,
      "relation": "negativeCorrelation",
      "evidence": "An additional “knot” of tau being entangled in epigenetic landscape of neurodegeneration comes from the finding that by acting as a HDAC6 inhibitor, tau is being indirectly involved in both (dys)regulation of transcriptional activity and impairment of autophagic clearance by the ubiquitin proteasome system [81,82].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 33,
      "target": 57,
      "key": "80ee8d5b2c402decd6a32839ceb7c454a8c53450e10238a56d355cc53ffbbf89203b922716b564e487a13c5803f27746b7cf53ab2f283204be3e544400c70161"
    },
    {
      "line": 164,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 42,
      "target": 99,
      "key": "b71c0720905eda8b25052257ffd64d019771fe4bb1bcdeb2fbb624d9651891825fed2bf124bc29cfa1416a65b33ecf82d70a09eb9c18c7a337bf3a9e8cfc5e9a"
    },
    {
      "line": 165,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 42,
      "target": 98,
      "key": "e623e63650876aeb23e76396d6996ba58af4598bf9598018b5369fdbef1128ed0376fc9cae8bfe4c578937a2ed93266e1d58b075d77243c2bfb3f18c8d144ed3"
    },
    {
      "line": 166,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 42,
      "target": 104,
      "key": "6611cee75753a33ffec1254daf1ea160fbdb0ff205ca0087e266056dcb7ebbc565193e441cf417e7e80928113390dae554da03c94b9686fc0d5593fb6f5c528c"
    },
    {
      "line": 164,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 99,
      "target": 42,
      "key": "176b6dd210b6b40c32960551b396efe756d4556627c9de17b2ef1149e7d230db84cf5de4fde9dde79315a5d2c5b946381502c08a91423af9d1d190d7a66e0a65"
    },
    {
      "line": 165,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 98,
      "target": 42,
      "key": "66c14057aa5e0d373c90fbe15f9d4d05ab873b9ea1a574507a7c6ead9ebaf9126b5290b7ea7eaa7e8cba86823bcccf3d533f1d0b52cf01b54e048e9198a75db0"
    },
    {
      "line": 166,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 104,
      "target": 42,
      "key": "c50e994046aab899cabd6f57627394b555b822035bb523b627452c9cc3b116f517c0dbdfb8d1a6aaca739d67414c9bd9bdd4c337ea5f77d6ae5bc19bb95655be"
    },
    {
      "line": 168,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 41,
      "target": 102,
      "key": "dc82aeff0e55cb5decc00940ee1e365597299c81e50c86e567b140b0b8284ffd09b7b0b13d047be24011cf387b964d276d0c0eb674801e3000ae88fcd06540b5"
    },
    {
      "line": 168,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 102,
      "target": 41,
      "key": "401007aa644d5c7e9de8f9d45b5476ef911daaf5b852637d8499a4c9c4e4e4c5f9704470b450736c6729a813f033f825de4c4d17605ad199b331e0395e6ba166"
    },
    {
      "line": 185,
      "relation": "positiveCorrelation",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 102,
      "target": 94,
      "key": "2151a6707705dd92c3998a05e41e4168906c28038b68faf115488574844eebd05469f7549a6a651f140f3f7c066d8e3803a3f780b762b7c57574f8136a7ad49c"
    },
    {
      "line": 175,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 90,
      "target": 101,
      "key": "2d2ae540083dbb47c53da88e2c8941b02e595188faacd31ac87c7145a76f0eb0f6644aeafb7cbcae98d0607115cdc83c95880c8c87ff0b0c8956f3f69b4605b5"
    },
    {
      "line": 175,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 101,
      "target": 90,
      "key": "8ef3a3419c27dc9a539ed42fb37d87c0928ff620241cf69c40857b3d0206a9a8569c9400f938a16c369b23afff2d7545c4f22177d22ad9424b425e706d0098b8"
    },
    {
      "line": 176,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 101,
      "target": 91,
      "key": "b1431a68c26a9ccc8c701a33e5a893950dfb882a9116d92c5a1be9c6bc32d9911e0b60e4f69f2d826beb87e997fb6baa1288105402a1270b9d523d611d4fb559"
    },
    {
      "line": 177,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 101,
      "target": 89,
      "key": "65c2c45102e6454b57878352ed079a9a29ed542c4e7bee1e7b2e6a8d10564d3d5626e46d840dc82102c3775b13acdf2ce8c7427186d0daccd0a535f33c7dbc1f"
    },
    {
      "line": 178,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 101,
      "target": 87,
      "key": "c9224d0b462b91607ad4874c05ea7ededf22bd7692a72c9b6e473fba44def6bf20a959e972c04afd8db5b6388402a1bc425e58140938966632cda289b46d1b32"
    },
    {
      "line": 184,
      "relation": "positiveCorrelation",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 101,
      "target": 94,
      "key": "bf8db243fdb090bff7d3ad6c548cb6cb4ed4906ba35b0d377b0314e8d41b9bb8eea871b782cc2d6feb265132c535a1ec0f5bbab5c7446f648cab31b4f0a84a11"
    },
    {
      "line": 176,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 91,
      "target": 101,
      "key": "015327f4a9872cbef0e971fbac53fea1ec6b04003d6ee4266a8170c3e9ad1d1c77973bbb6ded7049c34b955998de5c1d4f4363affac69f27e4e7c9b5d8b0513f"
    },
    {
      "line": 177,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 89,
      "target": 101,
      "key": "95fa29ea9dfe4bbfa2d424096e9186648c2d1573c273f24414fc453aa727d521eddda8d604a9e2a9467ba44f5b64e7642951311ca1f1be12ad0fe898777ba73d"
    },
    {
      "line": 178,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 87,
      "target": 101,
      "key": "295b9b810c85154939421a9cd4d6544c9e42864917caf428805626d38fc9cb3f7e8558b67774774808217652a66ac17d22ec7d7ba5f0cef1d3a83193071d758b"
    },
    {
      "line": 184,
      "relation": "positiveCorrelation",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 94,
      "target": 101,
      "key": "d412bebd2d3636dbc7953bd6b1ba45b48699d15bd4dbcbd1ee0500e8ea450c2fc9cff3f5e440c146a19dccc5792baa73cdb68abb870a47f6bc4b0b7062e654f6"
    },
    {
      "line": 185,
      "relation": "positiveCorrelation",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 94,
      "target": 102,
      "key": "9c4d387a8e4805fdc03c571a1210c7e02bc61ea369cadc988bcc316203b6ad9331c6062c986736303bdd7aafbef2cc84e7eed0176e2da30e3630d5af6265d353"
    },
    {
      "line": 186,
      "relation": "causesNoChange",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 94,
      "target": 0,
      "key": "d5f4321191be9857ea84dd3ad827d1e57b9de2c2f62c939f139eed9443cfecbf5e7bef940ef5107e432b6be48469b5c3442845091c0535f16f718d93f17751a9"
    },
    {
      "relation": "hasVariant",
      "source": 93,
      "target": 94,
      "key": "bac52af0d0adc7830aca23c4cc56ac599002e35db60c9a57dea1d3577f276c6ac7b3076dad0813a4928ae1bbe5cbc1d0d10439f18b9f09285e6540dd3d850672"
    },
    {
      "line": 188,
      "relation": "association",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 37,
      "target": 103,
      "key": "ed69e3d6615a2da201debc3ad91c03831bb90cd626da972958a6aaca0db3949a747627d911f84d02cd80dbed7f28a3a7f17ea58fbe3c8cc8a1be7f9e0f173e73"
    },
    {
      "line": 188,
      "relation": "association",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 103,
      "target": 37,
      "key": "d9f51278435ca136d35d80bc4ad32b362487b816357d16444f6a4c301fb2e6cdaf2214555465b243e8faffab20ce93a5db33ce7c610a3a4c868aa163322f6bc1"
    },
    {
      "line": 189,
      "relation": "association",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 103,
      "target": 36,
      "key": "fcb0823c86eb1bb6c81ee77233fe93527e7313338b84fa3feb8dbc51d3b35844251e1953d7c0eb6285b46e42ae386f94b4ceac6bc189ab118f56c04720a7dd2c"
    },
    {
      "line": 189,
      "relation": "association",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 36,
      "target": 103,
      "key": "368420dda3d044d037b5efd993914081522ea68a7c23afc9c939137d0bb3cabf31f9011d2e173a1c8df3a1521ef8a6762c96a470071f00f0661805b31838b797"
    },
    {
      "line": 195,
      "relation": "association",
      "evidence": "The tau fragment first isolated from the PHF core is approximately 100 amino acids in length. Its N-terminus was defined by sequence analysis [30,56], and its C-terminus was defined by epitope mapping of MN423. Immunoreactivity was shown to depend on a specific C-terminal trunctation at Glu391 [33,150].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 88,
      "target": 46,
      "key": "9a0f7707051f0c221b8e44c17712a7832a0cb109a5e3b44894bd39ece8609907922b3826e4aa0fe8e5428d2687973b0c8f7d9d825073755c1a9ec3cbe9c146c7"
    },
    {
      "line": 195,
      "relation": "association",
      "evidence": "The tau fragment first isolated from the PHF core is approximately 100 amino acids in length. Its N-terminus was defined by sequence analysis [30,56], and its C-terminus was defined by epitope mapping of MN423. Immunoreactivity was shown to depend on a specific C-terminal trunctation at Glu391 [33,150].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 46,
      "target": 88,
      "key": "8992f67b82af658ff56922b34f6a7ed811e39f9d4d8dc0ab1b50dc40167f0410a9f1e4e5d1637f9c4a842f97219c0d7f353e98b5e242c6c2ce5be277e748917d"
    },
    {
      "line": 196,
      "relation": "partOf",
      "evidence": "The tau fragment first isolated from the PHF core is approximately 100 amino acids in length. Its N-terminus was defined by sequence analysis [30,56], and its C-terminus was defined by epitope mapping of MN423. Immunoreactivity was shown to depend on a specific C-terminal trunctation at Glu391 [33,150].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 46,
      "target": 20,
      "key": "78a1c02d3631575bc99d2a4127ce52a73cc81cb2dc3276b96dda2d31683b48dfb70ae64affa49f17523f5afab8e41c9a94005fd3acb1c33ca296eab0fe7e99a2"
    },
    {
      "line": 201,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 20,
      "target": 105,
      "key": "ac2f8c88e709f87dd4fb3b02d36346212a88e7df9968af1b83805ccde3e9f25426ab4175ad7eb0bd1d4c2ca16db70e03d558213242c79ec5caff26a855bebad7"
    },
    {
      "line": 202,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 20,
      "target": 95,
      "key": "4cd60e41461bc88cd184d6d00cb126d7dfcc66823bd046399c600d1c5923fdf1ccdeb7d31eb637424150eebdc6dcd76a32128af910fc282298c8864b9ed21f1f"
    },
    {
      "line": 203,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 20,
      "target": 97,
      "key": "d39df2373253b6de6aad727dfb55193ba08566356165d326f83db566bdbd838864da96ef2ffa5904fa30ca115ab0b7742d418ecb16b6069ca26258af595e974e"
    },
    {
      "line": 201,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 105,
      "target": 20,
      "key": "9935918cf1fd993ef09a1110daa665c8ea8348a3d91118e73c54d26081a25d76090d697456845f349cfcef2a395eaedbc331c91b02eef030a43dde19d8c0ad95"
    },
    {
      "line": 202,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 95,
      "target": 20,
      "key": "9a570e0fab93d148f476645f7908fa8122d95fdd69298545fcfea2a2e471cd455dee9d32839c5ec00875ba3b16cb2f94666f769b77b776168c7f4ccfba9aba81"
    },
    {
      "line": 203,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 97,
      "target": 20,
      "key": "1931562668095c85e4707a496a2395517d90ba2ae7ab2164938f6fe9ce543d1d4810dbe61684b13b8f141040e437d2f76ccc717a445b96f263d396813bc63d6a"
    },
    {
      "line": 208,
      "relation": "positiveCorrelation",
      "evidence": "The most recent data obtained indicate that tau pathology indeed may be induced and propagated after the injection of tau oligomers or aggregates in either wild-type or mutated MAPT transgenic mice [164], and that tau aggregates can be transferred from cell to cell in vitro [164,165] and in vivo [166,167].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 21,
      "target": 21,
      "key": "7bf73cfa375cdaae4779c9a7cddf579df588fe8a40788c7833fda2543e708ca209b48a20b819ad597a2cd423d20dbe4fd1cc164a49a507b152602901200e0fed"
    },
    {
      "line": 208,
      "relation": "positiveCorrelation",
      "evidence": "The most recent data obtained indicate that tau pathology indeed may be induced and propagated after the injection of tau oligomers or aggregates in either wild-type or mutated MAPT transgenic mice [164], and that tau aggregates can be transferred from cell to cell in vitro [164,165] and in vivo [166,167].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 21,
      "target": 21,
      "key": "ac3cd0fc8ff4b1bfab6b7dff54908d1c9506b0ffbeebec17b5fe7595498f6bbb514147a6ed1cb0df737b0d41d7500818e375cd39fb7c651adc4d233f614218c8"
    },
    {
      "line": 217,
      "relation": "positiveCorrelation",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 29,
      "target": 57,
      "key": "987b537addfd44057188b05bd7faffc8c2e2d6983bfaccad961b32767f514413b64a9790f436d449b31bbe7e7f59cfcefe11513b1930f47e1fe3d43d239d65a6"
    },
    {
      "line": 224,
      "relation": "isA",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 29,
      "target": 21,
      "key": "73319448b7eca84e996228381066ba9a3fd4211a14f7ce2bed14e67714837eb2dc0aa325e7f24f3c0379561822ac619bc3a9a61b1303d1bde255bd6456a0887b"
    },
    {
      "line": 218,
      "relation": "association",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 43,
      "target": 8,
      "key": "264ab7e8418ee10b2db6345a9308af44bb279e08e9c4ba13c9d1409ec3724b5ed7d33ac769be9f8f227f7cfef6abf88386725bafff89e70c0a49eca58e096196"
    },
    {
      "line": 219,
      "relation": "increases",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 43,
      "target": 35,
      "key": "9f22515aeab04f5ec683d6f499fc71136bcf0dc539ffd0391e6386ecc93e988da27985c5b8c57a92977f831ec7e2aa1e484598fd7c7a5bfd7d1fb9e0db1a7502"
    },
    {
      "line": 249,
      "relation": "positiveCorrelation",
      "evidence": "Recently, it has been proposed that tau protein acetylation may be responsible for tau aggregation in AD. Grinberg and collaborators detected tau acetylation at Lys274 in all tauopathies (both primary and secondary), except in AgD",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 43,
      "target": 58,
      "key": "cbcd85a7f7322c600d736f64343f92b5c352ea380ac781aeba3fd25c981157d243acd5c28371488bba04e53782aa6bbc7e7a11f14edfbf697e700bba5333e6e3"
    },
    {
      "line": 218,
      "relation": "association",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 8,
      "target": 43,
      "key": "c04eda6adc6f48d82dfa299ece516d58e24a6c8c43e5061073cbb472b63d7cd60042b0682afdd1ba97cf9d6aa50fcf94ccff84c27e81383bc303bbf9a37a2e15"
    },
    {
      "line": 220,
      "relation": "partOf",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 8,
      "target": 35,
      "key": "8429d1a7d2c824afae5b257d581baa64db8fc8f5cd572dfdb332b2749d43de45fdf26489d5fff8f1a84de95e4808f28b26ba0249ca4897d4265e54606620b86f"
    },
    {
      "relation": "hasComponent",
      "source": 35,
      "target": 8,
      "key": "3bf31bc9d56fa49ae100ac6176a8b3d8ff7cf3a93d204a336c8f69f9ac4e03500e3c32b74164ece368c9e9270c17f0dc327313cd5680686e326b508dd789723e"
    },
    {
      "relation": "hasComponent",
      "source": 35,
      "target": 43,
      "key": "158011fc2cfdf300f52510b6c098ec0b69a9b49afd8eb147092d7c23ef2865716ab866b89a201281946c94c838511a8ad6fff5232a06e7d6299f82d751f41bb8"
    },
    {
      "line": 221,
      "relation": "positiveCorrelation",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 35,
      "target": 32,
      "key": "3587754b45964bf42ba328703ac468e1aecd325d77f8dbdf768375a4e20f1aa9a2804416e5be65f4516142e82f1a2aa2597f4c9ffada9b2091692c7971f51c4b"
    },
    {
      "line": 221,
      "relation": "positiveCorrelation",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 32,
      "target": 35,
      "key": "f2c2e9e9b90ee1316a76a065ed4ed5b20e12fa12ab213fc7e7a3e63534e4c6b6d2e2ee6876d85f6d6fe0f25cc4b6450cc4cb8423a089970df73690eb2bb06193"
    },
    {
      "line": 223,
      "relation": "isA",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 32,
      "target": 21,
      "key": "24bd1bf43abb1a8d103b387db43c591b4aaeaa59812d0f5e21d4d8db74a206b1e88b6a18994c0e31a91e97da284994a1367bcaa92033d42e24311d23a40f7d27"
    },
    {
      "line": 225,
      "relation": "isA",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 28,
      "target": 21,
      "key": "1b04ea43e2eb034e8f58e3ca1431df9aede87f400a0a67c69d6306558c4049479228227bce7d849708a166274a4b4f1530dc9641d4036544ea565fd8b745e1db"
    },
    {
      "line": 226,
      "relation": "increases",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 19,
      "target": 21,
      "key": "45ae793fa48745830fa19f7df50420848aab589c46e0b045e98b66252f5c8153bfc416b811f1e87c1b4bb7a3e0bbdde80346eb8621f503c8a29a5cf64147765c"
    },
    {
      "line": 230,
      "relation": "decreases",
      "evidence": "Green coffee, a non-toxic small molecule, found to be an inhibitor of protein phosphatase 2A methylesterase, was shown to improve cognitive and motor performance in mouse models with tau pathology",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 39,
      "key": "a25c373f74c0a912f7bc26154b193105e97dd3967e3173993758ad5b95e118629e890928432374c115319055e324360db6017348f5e13e15d032b2b6f897019e"
    },
    {
      "line": 231,
      "relation": "positiveCorrelation",
      "evidence": "Green coffee, a non-toxic small molecule, found to be an inhibitor of protein phosphatase 2A methylesterase, was shown to improve cognitive and motor performance in mouse models with tau pathology",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 34,
      "key": "12dcc795accfae2b842c39ea8e73df9b0844bf86c263c063978db67736812bdf3789bde055d3fa0e6b79d02c169ebdcf98db2629a29b7bd1e9c817708b42e4eb"
    },
    {
      "line": 231,
      "relation": "positiveCorrelation",
      "evidence": "Green coffee, a non-toxic small molecule, found to be an inhibitor of protein phosphatase 2A methylesterase, was shown to improve cognitive and motor performance in mouse models with tau pathology",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 34,
      "target": 3,
      "key": "125d155de6156a4f71794e70a488a03bba0933595baa0fb8c114d14c1776b4b7c8212ad107e73347c4850d6d3f531efceb6e982a4a52be0eb02cafbe8335eac2"
    },
    {
      "line": 236,
      "relation": "increases",
      "evidence": "A quite different strategy is to target tau clearance—e.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 15,
      "target": 31,
      "key": "4312191070867dd437cbf42be447e46b196aa8dcf40ac8a38e896624af4c2695a208411468e68f21bc3421d21635ea506e9c67b6397fb268773e16935aa0210f"
    },
    {
      "line": 237,
      "relation": "decreases",
      "evidence": "A quite different strategy is to target tau clearance—e.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 31,
      "target": 57,
      "key": "ecf1ba2592d2d3f91f5d039786bc86cb5a471a80034b8d2269323b1217e44dc7edd5ee826c2772a2a227a6f47776d4a124030cacbfdd3e06801004a0723863dc"
    },
    {
      "line": 238,
      "relation": "decreases",
      "evidence": "A quite different strategy is to target tau clearance—e.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 44,
      "target": 72,
      "key": "05e15921a83678f7cb401857c8c9a3a636012d1b6bd730461197d46cf4a397ab101829aeac70adee18966686b298653b047f6c6504ca9cd9217ba49e3624a4c8"
    },
    {
      "line": 243,
      "relation": "decreases",
      "evidence": "MB is a phenothiazine that crosses the blood brain barrier and acts as a redox cycler. Moreover, besides its beneficial properties as being able to improve energy metabolism and to act as an antioxidant, it is also able to reduce tau protein aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 1,
      "target": 43,
      "key": "e59734f640d875806be3668a0ef970c793b509421bb79a10e28bfeb9a41734159df45cff6d330cd40eddaa9e38b64d2c93c877ae8a1c30479081ba5fe66aae4c"
    },
    {
      "line": 244,
      "relation": "decreases",
      "evidence": "MB is a phenothiazine that crosses the blood brain barrier and acts as a redox cycler. Moreover, besides its beneficial properties as being able to improve energy metabolism and to act as an antioxidant, it is also able to reduce tau protein aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 49,
      "key": "cb1106737af558a125ff854ebd50d99cffd1c9db65e8af2a58a020fe9a32328b0a632fb655706efc3a4d9e199b3733552fdc54ebf62bdd043c3a875f359cd51d"
    },
    {
      "line": 245,
      "relation": "decreases",
      "evidence": "MB is a phenothiazine that crosses the blood brain barrier and acts as a redox cycler. Moreover, besides its beneficial properties as being able to improve energy metabolism and to act as an antioxidant, it is also able to reduce tau protein aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 50,
      "key": "c7cb295d3d788d4c588ddabaa5d5448ca51140adde35814e3bbd89d0d81e9e731905ee128632f4266ac6d892861591aa7480e66c0c6c91a290657791ffde492d"
    },
    {
      "line": 249,
      "relation": "positiveCorrelation",
      "evidence": "Recently, it has been proposed that tau protein acetylation may be responsible for tau aggregation in AD. Grinberg and collaborators detected tau acetylation at Lys274 in all tauopathies (both primary and secondary), except in AgD",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 58,
      "target": 43,
      "key": "88acffc56c792aaaa763b4815b7c1f0764eb3a8806e80cb17568902ad0fab9ac79f161c4f4737760c64a1291e44b53a1a413dd5a5eda002ab6b8370a6b4f38aa"
    },
    {
      "line": 253,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 14,
      "target": 43,
      "key": "8eba196d2862222f9f3fefc4ee286b89cf06e9e65760228e0cde2a5c0df85ab509acf6ae32075b8d0d332d87c54daefff2c18d3e349c31347a5da0281fd14e5d"
    },
    {
      "line": 254,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 25,
      "target": 43,
      "key": "f6d0e654486dac8b80a5df5df21d0c98f773ab4b561c30b92f048d8c6b855e38028a485b6568c930c2f237b0b199be7ee23c9597330dc2b0d90159a36f5df43d"
    },
    {
      "line": 255,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 23,
      "target": 43,
      "key": "eac5fafd11d15ee91275b849d5b653c93c28606435085e498501a0b6cc9411ba7925cb2e48783cbdc5f6ccf05e218788c7ed212eff585d1eee3a00d6576caf7a"
    },
    {
      "line": 256,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 26,
      "target": 43,
      "key": "2c13499388c2105b40f6e09e04047c0fc54ba0e7b99343138681b5a7f1c36dd261052d2319e955920eb64eb3fd805d0d55fd90ded3446598e751bc447f7dc2b8"
    },
    {
      "line": 258,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 16,
      "target": 43,
      "key": "4fb0e9d949c0eda66d7acb5367a5c0525f2f5aea5724d6b7ec33b37c9e9663e4311f3fcb4318df89eb3b1f809d30faf57722dfbe0353fa5a199c7d1a9198f3e7"
    },
    {
      "line": 259,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 24,
      "target": 43,
      "key": "c648c5e92bc8e11576e71c63a33c7104f8d81b6700cdddbe9aa1790cdbe39f16e6525e0cec76ad2df7971801a08f1d42867c7dc811a8cef4f5e308461cdde938"
    },
    {
      "line": 260,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 10,
      "target": 43,
      "key": "9cdf4a190a082aaef14190a4bbb26717a76cccf4bbf0c057069cc41a3d7b256c67224840b40b8016d91887af2458e4892f490a9ac606ed6a817a50ee4b20117b"
    },
    {
      "line": 261,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 4,
      "target": 43,
      "key": "54fa723daac53bcdf9c856f5ad4943806282560dad81b24140ff6a8b84ca2a9d3c2b32e9eacb09e0e6963744d4b0717c09129e9f7115f1e39160513bc9696ce6"
    },
    {
      "line": 262,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 9,
      "target": 43,
      "key": "39779b7df7b2f518fd863b8c40517627498e11625657196766b8290c08fa65003c9b249befc345816ac4eaf5c009d8a480796673692072ec27b147c14a251503"
    },
    {
      "line": 263,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 22,
      "target": 43,
      "key": "588661b3010bdfdd2f0129780d57ee7af1c7f3a42be954a64bc1811d2487b5451edbbea19b07e367628cffd9665bf953f830ad3203dd3f78072575c8768e1070"
    },
    {
      "line": 265,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 11,
      "target": 43,
      "key": "92cb1311d3aa2ee7265b0646b010fa637415ccd57af360f465833783165f05f70f2a1b7bf0034914c96dda0227462f10cf5078c072ca412086b17b1e0a2d44b4"
    },
    {
      "line": 267,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 7,
      "target": 43,
      "key": "502aabf691a0cddcba5990db36c097fc0c41b16b5bfb9781ffee384f159394654c5820f4a3ea4f412fbd5ca33315cafb06a0b741661c590f0d360a45066ec1ab"
    },
    {
      "line": 268,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 5,
      "target": 43,
      "key": "9539f4de2f25cad96204445f3001ea67fc9d912dd4a8f8e8e726ad7fdab7baadb282b6aeb012731fcb6cebf158854b515dfc551bf6f7b631a0a4e76f37eaeef7"
    },
    {
      "line": 269,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 6,
      "target": 43,
      "key": "cafe6957593c74852126108eef81a739b7780e2919475fa7e37a0db07f91c4374886f7756c6d267e75b52e6ae249d7e62e8d5221d8817e9b6f33d9aba30a05ac"
    },
    {
      "line": 270,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493"
      },
      "source": 13,
      "target": 43,
      "key": "c3a86422c33d7fdae2d208ddfe7e3b08b7c94e9134a82d9f638a01ed28a77c9ad1be48e7f53bf29013bf7e9c85055dd7d79b607fd321503d99ec1b0e6be0df27"
    }
  ]
}